Use of fentanyl and safety of endobronchial ultrasound.

journal.publications.chestnet.org Financial/nonfi nancial disclosures: The author has reported to CHEST the following confl icts of interest: Dr White has research funding from the National Institutes of Health unrelated to the content of this article. He is the president of the American Society of Hypertension, Inc for 2012 to 2014. Dr White is a consultant regarding the cardiovascular safety of numerous noncardiac drugs and devices (steering committees, data safety monitoring committees, and cardiovascular end point committees) for companies including Ardea Biosciences, Inc; AstraZeneca; Forest Research Institute, Inc; Eli Lilly and Company; Roche; Teva Pharmaceutical Industries, Ltd; and Takeda Global Research and Development Center, Inc. Correspondence to: William B. White, MD, Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030-3940; e-mail: [email protected] © 2013 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details. DOI: 10.1378/chest.13-1315